Translational Development Acquisition Corp. (NASDAQ:TDACU – Get Free Report) saw a significant increase in short interest in the month of August. As of August 31st, there was short interest totaling 6 shares, an increase of 100.0% from the August 15th total of 3 shares. Based on an average trading volume of 20 shares, the days-to-cover ratio is currently 0.3 days.
Translational Development Acquisition Price Performance
Shares of NASDAQ TDACU traded down $0.07 during trading on Tuesday, hitting $12.50. Translational Development Acquisition has a 12-month low of $10.71 and a 12-month high of $17.29. The company’s 50 day simple moving average is $12.11 and its 200-day simple moving average is $11.47.
About Translational Development Acquisition
Translational Development Acquisition Corp. is a blank check acquisition company incorporated in Delaware. The company was formed to effect a merger, stock purchase, asset acquisition, stock exchange, reorganization or similar business combination with one or more businesses, though it has not yet identified a target for its initial transaction.
In early 2021, the company completed its initial public offering and listed its units on the Nasdaq under the ticker TDACU. Each unit comprises one Class A ordinary share and one-third of a warrant to purchase additional Class A shares, with its securities also trading separately as shares and warrants.
Following its IPO, the net proceeds from the offering are held in a trust account until the closing of an initial business combination.
See Also
- Five stocks we like better than Translational Development Acquisition
- Cashing in on the Qubit: NVIDIA Takes the Quantum Leap
- Ready to Rumble: Anthropic Rings the AI Bell
- Breaking Down the Impact of the CHIPS Funding Deal for Quantum Firms
- Could Dave & Buster’s Capitulation Signal the Bottom Is Finally In?
Receive News & Ratings for Translational Development Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translational Development Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
